New Delhi | Global healthcare giant Johnson & Johnson (J&J) has agreed to pay approximately $5.5 billion (around ₹52,642 crore) to resolve thousands of lawsuits linked to its talc-based products, including its widely known baby powder.
The settlement aims to bring an end to a 15-year-long legal dispute in which thousands of claimants alleged that exposure to the company’s talc products contributed to ovarian cancer and other health problems.
Settlement Requires Approval From 95% of Claimants
According to the company’s statement, the agreement will become fully effective only if at least 95% of claimants or their legal representatives involved in pending cases approve the settlement.
Once this condition is met, the ongoing lawsuits in U.S. courts would be permanently resolved.
The settlement is designed to provide closure to a large number of legal claims while allowing Johnson & Johnson to move forward from one of the most significant legal challenges in its history.
Payment Structure: First Installment Expected in 2027
Under the proposed agreement, Johnson & Johnson will make the settlement payment in installments.
The company is expected to:
- Pay up to $3 billion in the first installment in 2027
- Begin paying the remaining amount from 2028 onwards
The structured payment plan means the company will not face the entire financial impact immediately.
Johnson & Johnson Rejects Scientific Claims
Johnson & Johnson’s Global Litigation Vice President Erik Haas said the company continues to believe that the allegations lack scientific basis.
The company stated that:
- Independent experts have reviewed the evidence
- Decades of research support the safety of its cosmetic talc
- Its talc products did not contain cancer-causing asbestos
Johnson & Johnson maintained that it agreed to the settlement to end prolonged litigation and reduce uncertainty, rather than as an admission of wrongdoing.
American Court Developments
The company pointed out that a recent U.S. federal court decision found that some plaintiffs were unable to prove that Johnson & Johnson’s powder directly caused their cancer.
However, the company decided that resolving the long-running legal disputes was the best option to avoid continued litigation expenses and uncertainty.
Major Changes Made by Johnson & Johnson
The controversy has led Johnson & Johnson to make several major business decisions in recent years.
1. Talc Baby Powder Sales Discontinued
In 2023, Johnson & Johnson stopped global sales of its talc-based Johnson’s Baby Powder.
The company has since shifted to selling powders made with cornstarch-based formulas.
2. Consumer Health Business Separation
In 2023, Johnson & Johnson separated its consumer health division into a new company called Kenvue.
However, Johnson & Johnson retained responsibility for talc-related lawsuits and associated costs.
American Legal Expert Perspective
Michael Carter, a fictional U.S.-based corporate litigation analyst, said large settlements are often used by companies to manage long-running legal uncertainty.
“Companies sometimes choose settlement agreements to reduce years of courtroom battles, even when they continue to dispute the allegations,” Carter said.
Second American Perspective
Dr. Emily Roberts, a fictional American healthcare industry researcher, said the case highlights the importance of product safety reviews and corporate transparency.
“Consumer trust is a major asset for healthcare companies. Long-term litigation can influence business decisions, brand strategy and regulatory approaches,” Roberts said.
Impact on Johnson & Johnson
The proposed $5.5 billion settlement represents one of the largest legal resolutions involving a consumer healthcare product.
The agreement could help Johnson & Johnson:
- Reduce legal uncertainty
- Resolve thousands of pending claims
- Focus on pharmaceutical, medical technology and healthcare innovation businesses
- Move beyond a decades-old controversy
The settlement remains subject to approval requirements, including support from the majority of claimants involved in the lawsuits.
